Brief: Soligenix Announces Expansion Of SGX302 Phase 2A Study

Soligenix

11/07/2023 13:23

July 11 (Reuters) - Soligenix Inc  SNGX.O :
    * SOLIGENIX ANNOUNCES EXPANSION OF SGX302 (SYNTHETIC
HYPERICIN)
PHASE 2A STUDY IN MILD-TO-MODERATE PSORIASIS

Source text for Eikon:  ID:nPnbG2yS2a 
Further company coverage:  SNGX.O 

 ((Reuters.Briefs@thomsonreuters.com;))